ClinicalTrials.gg
CompletedNCT04617509Updated Aug 31, 2021Results posted

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

A Phase 1 interventional study of Formulation A GS-248 and Formulation B GS-248 in Pharmacokinetic, sponsored by Gesynta Pharma AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-31.

Sponsored by Gesynta Pharma AB · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study will collect information about pharmacokinetics (PK), safety and tolerability following a single dose of GS-248 in two different oral solid formulations in capsules to healthy subjects. It will also collect information about pharmacokinetics (PK), safety and tolerability following a single dose of one of the two formulations of GS-248 in fed condition.

Read the detailed description

The study is divided in two parts. Part I will evaluate PK, safety and tolerability of a single oral dose of two different formulations of GS-248 in fasting conditions. Part II will evaluate PK, safety and tolerability of one of the two different formulations of GS-248 in fed conditions.

In Part I, a single oral dose of GS-248 in two different solid formulations will be administered to 14 healthy subjects. All subjects will first receive Formulation A and then Formulation B. A wash-out period of at least 4 days will be applied between the IMP administrations. Both doses contain 120 mg GS 248. For Part I, subjects will come to the clinic for single dose administration of Formulation A or Formulation B, respectively, and PK and safety assessments. Safety assessments include AE reporting, physical examination, ECG, vital signs, body temperature, and blood sampling for analysis of safety laboratory parameters.

After evaluation of the PK profiles of Formulation A and B in Part I of the study, one formulation will be selected to be given following intake of a standardised breakfast in Part II of the study. Subjects will return to the clinic for a second dose of the selected formulation, yet now in fed conditions. The assessments during fed conditions will be the same as during fasting conditions except that the subjects will consume a high-fat high-calorie breakfast 30 minutes prior to IMP administration.

02

Conditions studied

  • Pharmacokinetic

Keywords

  • Pharmacokinetic
03

In context

Lead sponsor

Gesynta Pharma AB is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written for participation in the study.
  2. Healthy male or female subject aged ≥ 18 and ≤70 years.
  3. (BMI) ≥ 19.0 and ≤ 30.0 kg/m2.
  4. Clinically normal medical history, physical findings, vital signs, and laboratory values at the time of screening, as judged by the Investigator.
  5. Women of child bearing potential () must practice abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the subject) or must agree to use a highly effective method of with a failure rate of \< 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD]or intrauterine hormone-releasing system [IUS]) from at least 4 weeks prior to dose to 4 weeks after last dose.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to GS-248.
  2. Females who are breast feeding or who plan to become pregnant until 2 weeks after the end-of-study visit.
  3. Positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at screening and within 24 h prior to the first administration of IMP.
  4. Regular use of (inhaled and systemic), NSAIDs, aspirin or coxibs, antacids, PPIs, or any other medication that changes gastric pH within 14 days of study drug administration.
  5. Regular use of any prescribed or non-prescribed medication including analgesics, herbal remedies, vitamins and minerals within 2 weeks prior to the (first) administration of IMP, except hormonal and occasional intake of paracetamol (maximum 2000 mg/day; and not exceeding 3000 mg/week) and nasal decongestants without cortisone, antihistamine or anticholinergics for a maximum of 10 days, at the discretion of the Investigator.
  6. Presence of inherited or acquired disorders of function, bleeding or coagulation, as judged by the investigator.
  7. History or presence of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  8. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:

    • Systolic blood pressure \<90 or >140 mmHg, or
    • Diastolic blood pressure \<50 or >90 mmHg, or
    • Pulse \<40 or >90 bpm
  9. Positive test for serum surface antigen (HBsAg), virus antibodies (HCVAb) or 1 and/or 2 antibodies at screening.
  10. Presence or history of drug and/or alcohol abuse and/or excessive intake of alcohol and/or history, or current use, of anabolic steroids, as judged by the Investigator.
  11. Positive test for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP.
  12. Participation in other interventional studies within 3 months prior to administration of study drug.
  13. Consumption of grapefruit, grapefruit juice, other grapefruit-containing products, or Seville oranges within 14 days of first IMP administration.
  14. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  15. within the past 5 years with the exception of in situ removal of basal cell carcinoma.
  16. Any planned major surgery within the duration of the study.
  17. Prolonged (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting , as judged by the Investigator.
  18. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
  19. Regular excessive caffeine consumption defined by a daily intake of >5 cups of caffeine-containing beverages.
  20. Intake of xanthine- and/or taurine-containing energy drinks within 2 days prior to screening and prior to IMP administration.
  21. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during three months prior to screening.
  22. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
  23. Estimated (eGFR) \< 50 mL/min/1.73 m2 (determined by the revised Lund-Malmö GFR estimating equation).
  24. Subjects with swallowing disorders, which may affect the subject´s capability to swallow the IMP.
  25. Subjects who are vegetarian or for other reasons cannot eat the high-fat high-calorie breakfast.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Part I GS-248 Formulation A

    Formulation A given in fasting state.

    Drug: Formulation A GS-248

  • Active comparator
    Part I GS-248 Formulation B

    Formulation B given in fasting state.

    Drug: Formulation B GS-248

  • Other
    Part II GS-248 Formulation A or B

    Formulation A or B given in fed condition

    Drug: Formulation A GS-248 · Drug: Formulation B GS-248

Interventions

  • DrugFormulation A GS-248

    Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

  • DrugFormulation B GS-248

    Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

06

What researchers measure

Primary outcomes

  1. Cmax

    The Maximal Plasma Concentration (Cmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  2. AUC0-inf

    The Area Under the Curve (AUC) for the time interval 0-infinity of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  3. AUC0-24h

    The Area Under the Curve (AUC) for the time interval 0-24h of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 for the time interval 0-24 h was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: From time 0 (time of dosing) to 24 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  4. Tmax

    Time to Cmax (Tmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  5. T1/2(z)

    Plasma half-life associated with the terminal elimination phase (T1/2(z)) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: T1/2 (z) was assessed for the terminal elimination phase up to 48 hours

  6. Vz/F

    The mean volume of distribution (Vz/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: Vz/F was assessed for the terminal elimination phase up to 48 hours.

  7. CL/F

    The mean total clearance (CL/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean total clearance (CL/F) was calculated by non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

    Time frame: CL/F was assessed for a single dose of GS-248 up to 48 hours.

Secondary outcomes

  1. Number of Treatment Related Adverse Events

    The grading of the severity/intensity (grade 1 to grade 5) of AEs followed the common terminology criteria for AEs (CTCAE) v5.0. AEs were assessed by the Investigator as "unlikely", "possibly" or "probably" related to the IMP. An AE was considered causally related to the use of the IMP when the causality assessment was "probable" or "possible".

    Time frame: AEs (including serious AEs [SAEs]) were collected from the start of IMP application in Part I until the end-of- study visit i.e. Visit 7, day 3, up to 30 days.

  2. Number of Clinically Significant (CS) Changes in Physical Examination

    A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A short version of physical examination included an assessment of selected body systems at the judgement of the Investigator but at least included cardiovascular, lung and abdomen. The results of the examinations were documented in the eCRF as normal, abnormal not clinically significant (NCS) or abnormal clinically significant (CS). Post-dose physical examination findings judged as abnormal CS were reported as AEs.

    Time frame: Physical examination was performed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.

  3. Number of Clinically Significant (CS) Changes in Vital Signs

    Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Vital signs were judged as normal, abnormal NCS or abnormal CS.

    Time frame: Vital signs ware assessed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.

  4. Number of Clinically Significant (CS) Changes in Resting 12-lead Electrocardiogram (ECG)

    Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. HR and PR, QRS, QT and QTcF intervals were recorded. Safety ECGs were reviewed and interpreted on-site by the Investigator. All ECGs were categorised as "normal", "abnormal, not clinically significant", or "abnormal, clinically significant".

    Time frame: ECG evaluation was assessed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.

  5. Number of Clinically Significant (CS) Changes in Safety Laboratory Parameters

    Blood samples for analysis of clinical chemistry and haematology parameters were collected through venepuncture or an indwelling venous catheter and sent to the certified clinical chemistry laboratory at Uppsala University Hospital and analysed by routine analytical methods. Urine analysis was performed at the research clinic using dip sticks. Safety laboratory parameters were judged as normal, abnormal NCS or abnormal CS.

    Time frame: Blood samples were collected at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.

07

Results

Posted Aug 31, 2021

Participant flow

The subjects were recruited from CTC's database of healthy volunteers and from advertising in media (including social media). Screening visits were performed at CTC research clinic. Recruitment period started 24MAR2020 (the day after approval received from IEC and CA) and lasted until 06APR2020 (date for last subject screened).

Period 1: Part 1 Formulation A
Participant flow — Period 1: Part 1 Formulation A
MilestonePart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Started1400
Completed1400
Not completed000
Period 2: Part 1 Formulation B
Participant flow — Period 2: Part 1 Formulation B
MilestonePart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Started0140
Completed0140
Not completed000
Period 3: Part 2 Formulation A Fed Cond.
Participant flow — Period 3: Part 2 Formulation A Fed Cond.
MilestonePart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Started0014
Completed0013
Not completed001

Outcome measures

PrimaryCmax

The Maximal Plasma Concentration (Cmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Mean · nmol/L
Cmax
nmol/LPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
Cmax508.6 ± 220.9384.5 ± 219.1289.5 ± 184.4499.5 ± 227.2
Statistical analysis
  • Part I GS-248 Formulation A vs Part I GS-248 Formulation B vs Part II GS-248 Formulation A in Fasting Condition (Partial Set) · Ratio of geometric means: 1.4514 · 90% CI 1.1110 to 1.4514
  • Part II GS-248 Formulation A in Fed Condition vs Part II GS-248 Formulation A in Fasting Condition (Partial Set) · Ratio of geometric mean: 0.5497 · 90% CI 0.3977 to 0.7597
PrimaryAUC0-inf

The Area Under the Curve (AUC) for the time interval 0-infinity of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Mean · h*nmol/L
AUC0-inf
h*nmol/LPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
AUC0-inf1491 ± 478.11182 ± 567.41119 ± 463.91494 ± 497.4
Statistical analysis
  • Part I GS-248 Formulation A vs Part I GS-248 Formulation B · Ratio of geometric mean: 1.3441 · 90% CI 1.0953 to 1.6495
  • Part II GS-248 Formulation A in Fed Condition vs Part II GS-248 Formulation A in Fasting Condition (Partial Set) · Ratio of geometric mean: 0.7327 · 90% CI 0.5910 to 0.9083
PrimaryAUC0-24h

The Area Under the Curve (AUC) for the time interval 0-24h of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 for the time interval 0-24 h was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
From time 0 (time of dosing) to 24 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Mean · h*nmol/L
AUC0-24h
h*nmol/LPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
AUC0-24h1420 ± 459.41104 ± 527.21014 ± 377.61419 ± 478.2
Statistical analysis
  • Part I GS-248 Formulation A vs Part I GS-248 Formulation B · Ratio of geometric mean: 1.3710 · 90% CI 1.1120 to 1.6904
  • Part II GS-248 Formulation A in Fed Condition vs Part II GS-248 Formulation A in Fasting Condition (Partial Set) · Ratio of geometric mean: 0.7083 · 90% CI 0.5728 to 0.8759
PrimaryTmax

Time to Cmax (Tmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Median · hours
Tmax
hoursPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
Tmax1.500 (1.00 to 3.00)1.500 (1.00 to 3.03)3.000 (1.00 to 4.03)1.500 (1.00 to 3.00)
PrimaryT1/2(z)

Plasma half-life associated with the terminal elimination phase (T1/2(z)) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
T1/2 (z) was assessed for the terminal elimination phase up to 48 hours
Reported as:
Mean · hours
T1/2(z)
hoursPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
T1/2(z)10.69 ± 2.91216.09 ± 15.2613.36 ± 9.91410.91 ± 2.902
PrimaryVz/F

The mean volume of distribution (Vz/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
Vz/F was assessed for the terminal elimination phase up to 48 hours.
Reported as:
Mean · L
Vz/F
LPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
Vz/F2071 ± 10353884 ± 29403110 ± 15882125 ± 1057
PrimaryCL/F

The mean total clearance (CL/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean total clearance (CL/F) was calculated by non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.

Time frame:
CL/F was assessed for a single dose of GS-248 up to 48 hours.
Reported as:
Mean · L/h
CL/F
L/hPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed ConditionPart II GS-248 Formulation A in Fasting Condition (Partial Set)
CL/F132.9 ± 50.59191.4 ± 105.0185.2 ± 76.08133.7 ± 52.56
SecondaryNumber of Treatment Related Adverse Events

The grading of the severity/intensity (grade 1 to grade 5) of AEs followed the common terminology criteria for AEs (CTCAE) v5.0. AEs were assessed by the Investigator as "unlikely", "possibly" or "probably" related to the IMP. An AE was considered causally related to the use of the IMP when the causality assessment was "probable" or "possible".

Time frame:
AEs (including serious AEs [SAEs]) were collected from the start of IMP application in Part I until the end-of- study visit i.e. Visit 7, day 3, up to 30 days.
Reported as:
Number · events
Number of Treatment Related Adverse Events
eventsPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Number of Treatment Related Adverse Events731
SecondaryNumber of Clinically Significant (CS) Changes in Physical Examination

A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A short version of physical examination included an assessment of selected body systems at the judgement of the Investigator but at least included cardiovascular, lung and abdomen. The results of the examinations were documented in the eCRF as normal, abnormal not clinically significant (NCS) or abnormal clinically significant (CS). Post-dose physical examination findings judged as abnormal CS were reported as AEs.

Time frame:
Physical examination was performed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Reported as:
Number · Number of abnormal CS events
Number of Clinically Significant (CS) Changes in Physical Examination
Number of abnormal CS eventsPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Number of Clinically Significant (CS) Changes in Physical Examination000
SecondaryNumber of Clinically Significant (CS) Changes in Vital Signs

Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Vital signs were judged as normal, abnormal NCS or abnormal CS.

Time frame:
Vital signs ware assessed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Reported as:
Number · Number of abnormal CS events
Number of Clinically Significant (CS) Changes in Vital Signs
Number of abnormal CS eventsPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Number of Clinically Significant (CS) Changes in Vital Signs000
SecondaryNumber of Clinically Significant (CS) Changes in Resting 12-lead Electrocardiogram (ECG)

Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. HR and PR, QRS, QT and QTcF intervals were recorded. Safety ECGs were reviewed and interpreted on-site by the Investigator. All ECGs were categorised as "normal", "abnormal, not clinically significant", or "abnormal, clinically significant".

Time frame:
ECG evaluation was assessed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Reported as:
Number · Number of abnormal CS events
Number of Clinically Significant (CS) Changes in Resting 12-lead Electrocardiogram (ECG)
Number of abnormal CS eventsPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Number of Clinically Significant (CS) Changes in Resting 12-lead Electrocardiogram (ECG)000
SecondaryNumber of Clinically Significant (CS) Changes in Safety Laboratory Parameters

Blood samples for analysis of clinical chemistry and haematology parameters were collected through venepuncture or an indwelling venous catheter and sent to the certified clinical chemistry laboratory at Uppsala University Hospital and analysed by routine analytical methods. Urine analysis was performed at the research clinic using dip sticks. Safety laboratory parameters were judged as normal, abnormal NCS or abnormal CS.

Time frame:
Blood samples were collected at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Reported as:
Number · Number of abnormal CS events
Number of Clinically Significant (CS) Changes in Safety Laboratory Parameters
Number of abnormal CS eventsPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
Number of Clinically Significant (CS) Changes in Safety Laboratory Parameters011

Adverse events

Collected over Adverse events, AEs (including SAEs), were collected from the start of IMP administration until the End-of-study Visit i.e. Visit 7, day 3, up to 30 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I GS-248 Formulation A0/14 (0%)0/14 (0%)6/14 (42.9%)
Part I GS-248 Formulation B0/14 (0%)0/14 (0%)5/14 (35.7%)
Part II GS-248 Formulation A in Fed Condition0/13 (0%)0/13 (0%)2/13 (15.4%)
Most frequent other events
Most frequent other events
EventPart I GS-248 Formulation APart I GS-248 Formulation BPart II GS-248 Formulation A in Fed Condition
HeadacheNervous system disorders6/143/141/13
Haemoglobin decreasedInvestigations0/140/141/13
AnaemiaBlood and lymphatic system disorders0/141/140/13
FlatulenceGastrointestinal disorders0/141/140/13
Rhinitis allergicRespiratory, thoracic and mediastinal disorders0/141/140/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Trial
Mean44.3 ± 17.1
Sex: Female, Male
Sex: Female, Male(Participants)Overall Trial
Female10
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Trial
Hispanic or Latino1
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Trial
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Overall Trial
Sweden14
Height
Height(cm)Overall Trial
Mean171.6 ± 10.8
Weight
Weight(kg)Overall Trial
Mean74.5 ± 17.14
BMI
BMI(kg/m^2)Overall Trial
Mean25.1 ± 3.7
08

Study locations

1 site
  • Clinical Trial Consultants AB
    Uppsala, 75237, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in May 2020, 1 month.

Results were first posted in Aug 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Nov 5, 2020
StartActual
Mar 31, 2020
Primary completionActual
May 27, 2020
CompletionActual
May 27, 2020
Results first posted
Aug 31, 2021
Last update
Aug 31, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04617509
Lead sponsor
Gesynta Pharma AB
Collaborators
CTC Clinical Trial Consultants AB, Research Institutes of Sweden
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Mar 31, 2020
Primary completion
May 27, 2020
Completion
May 27, 2020
Results posted
Aug 31, 2021
Last update
Aug 31, 2021

Study contacts

Helena Litorp, MD, PhD
principal investigator · CTC Clinical Trial Consultants AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion